Attack on so-called JUNK FOOD.
When teaching Public Health doctors, Emeritus Prof Nutrition G.BEATON PhD pointed out that there is NO JUNK FOOD. What is meant is CONCENTRATED food. All food has a nutrition value.
George Beaton, Ph.D
Professor Emeritus
Department of Nutritional Sciences
Department of Community Science,
Faculty of Medicine
University of Toronto
FitzGerald Building, Room 322
150 College Street
Toronto ON M5S 3E2 CANADA
Home Office Address (GHB Consulting):
9 Silverview Dr
Willowdale, Ontario M2M 2B2
CANADA
Tel: (416) 221 7409
Fax: (416) 221 8563
E-mail: g.beaton@utoronto.ca
Research
My long term interest relates to the estimation, interpretation and application of human nutrient requirements. A related interest in the assessment and evaluation of nutrient intake, and the error structure of dietary data (and implications for statistical analyses and interpretation of diet-based research). My interests extend into the area of assessment of efficacy and effectiveness of nutritional interventions in developing countries. In recent years I have been involved in two major efficacy studies - one relating to vitamin A and young child mortality and the other relating to comparative efficacy of daily and weekly iron supplementation. Both involved collection and secondary analysis of data from studies conducted in developing countries.
Although now retired I continue my activities and interests in a consultant role, working with UN agencies and national bodies (in Canada and the United States) involved in international nutrition. I no longer accept students but serve on study advisory committees when requested.
Selected Publications
Beaton, G.H., McCabe, G.P. Efficacy of Intermittent Iron Supplementation in the Control of Iron Efficiency Anaemia in Developing Countries: An Analysis of Experience. Micronutrient Initiative, Ottawa, 1999.
Tarasuk, V.S., Beaton, G.H. Women's Dietary Intakes in the Context of Household Food Insecurity. J Nutr 129:672-9, 1999.
Beaton, G.H. Recommended Dietary Intakes: Individuals and populations. Chapter 103 in Modern Nutrition in Health and Disease, 9th Ed. (M.E. Shils, J.A. Olson, M. Shike, A.C. Ross, eds.) Williams and Wilkins, Baltimore, 1999, pp 705-25.
Beaton, G.H. Iron needs during pregnancy: Do we need to rethink out targets? Am. J. Clin. Nutr. 72 (suppl):265S-71S, 2000.
SPORT TAXED in CANADA
Sport equipment and Sport Clubs have no TAX RELIEF. To outfit a AAA Goalie costs $5000 plus $750 TAX. A hockey AAA club can cost $3000/year TAX: $450.
23 September 2011
UK DAILY MAIL: GYNESONICS Inc- " VizAblate FAST-EU"
Gynesonics initiates VizAblate FAST-EU study for uterine fibroid treatment
Gynesonics, Inc., a women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids, today announced the start of, and initial treatments in, the FAST-EU Trial, a multicenter clinical study to demonstrate the effectiveness of the VizAblate® procedure for the treatment of uterine fibroids associated with heavy menstrual bleeding. The VizAblate® System is the only CE marked system that combines ultrasound image guidance with radiofrequency ablation to treat fibroids transcervically in an outpatient setting. Symptoms from uterine fibroids have been reported to affect as many as 24 million women in the European Union.
“The VizAblate® System represents a new and exciting approach to treating fibroids associated with heavy menstrual bleeding and has the potential to be a very important tool for the gynecologist. We are excited to be a part of this study and to have started treatments at our center.”
Centers in the Netherlands, the United Kingdom, and Mexico are participating in the study. Professor Hans Brölmann MD, PhD, Head - Department of Obstetrics and Gynaecology, Vrije Universiteit Medisch Centrum (FREE UNIVERSITY Medical Centre) in Amsterdam, Netherlands was the first physician to treat a patient in the FAST-EU study in the European Union. "The VizAblate® System represents a new and exciting approach to treating fibroids associated with heavy menstrual bleeding and has the potential to be a very important tool for the gynecologist. We are excited to be a part of this study and to have started treatments at our center."
Gynesonics, Inc., a women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids, today announced the start of, and initial treatments in, the FAST-EU Trial, a multicenter clinical study to demonstrate the effectiveness of the VizAblate® procedure for the treatment of uterine fibroids associated with heavy menstrual bleeding. The VizAblate® System is the only CE marked system that combines ultrasound image guidance with radiofrequency ablation to treat fibroids transcervically in an outpatient setting. Symptoms from uterine fibroids have been reported to affect as many as 24 million women in the European Union.
“The VizAblate® System represents a new and exciting approach to treating fibroids associated with heavy menstrual bleeding and has the potential to be a very important tool for the gynecologist. We are excited to be a part of this study and to have started treatments at our center.”
Centers in the Netherlands, the United Kingdom, and Mexico are participating in the study. Professor Hans Brölmann MD, PhD, Head - Department of Obstetrics and Gynaecology, Vrije Universiteit Medisch Centrum (FREE UNIVERSITY Medical Centre) in Amsterdam, Netherlands was the first physician to treat a patient in the FAST-EU study in the European Union. "The VizAblate® System represents a new and exciting approach to treating fibroids associated with heavy menstrual bleeding and has the potential to be a very important tool for the gynecologist. We are excited to be a part of this study and to have started treatments at our center."
Subscribe to:
Posts (Atom)